FibroGen, Inc. 0IL8.L Stock
FibroGen, Inc. Price Chart
FibroGen, Inc. 0IL8.L Financial and Trading Overview
| FibroGen, Inc. stock price | 1.31 USD |
| Previous Close | 16.59 USD |
| Open | 0 USD |
| Bid | 0 USD x N/A |
| Ask | 0 USD x N/A |
| Day's Range | 0 - 0 USD |
| 52 Week Range | 0 - 25.13 USD |
| Volume | 4.33K USD |
| Avg. Volume | 980 USD |
| Market Cap | 11.37M USD |
| Beta (5Y Monthly) | 0.782394 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.037 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0IL8.L Valuation Measures
| Enterprise Value | 1.41B USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.09793812 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 12.143 |
| Enterprise Value/EBITDA | -4.65 |
Trading Information
FibroGen, Inc. Stock Price History
| Beta (5Y Monthly) | 0.782394 |
| 52-Week Change | 44.36% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 25.13 USD |
| 52 Week Low | 0 USD |
| 50-Day Moving Average | 19.45 USD |
| 200-Day Moving Average | 16.35 USD |
0IL8.L Share Statistics
| Avg. Volume (3 month) | 980 USD |
| Avg. Daily Volume (10-Days) | 1.27K USD |
| Shares Outstanding | 84.98M |
| Float | 90.97M |
| Short Ratio | N/A |
| % Held by Insiders | 7.97% |
| % Held by Institutions | 82.78% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -264.63% |
| Operating Margin (ttm) | -270.63% |
| Gross Margin | -145.25% |
| EBITDA Margin | -261.17% |
Management Effectiveness
| Return on Assets (ttm) | -30.56% |
| Return on Equity (ttm) | -411.92% |
Income Statement
| Revenue (ttm) | 116.07M USD |
| Revenue Per Share (ttm) | 1.24 USD |
| Quarterly Revenue Growth (yoy) | -40.60% |
| Gross Profit (ttm) | -159212000 USD |
| EBITDA | -303137984 USD |
| Net Income Avi to Common (ttm) | -307153984 USD |
| Diluted EPS (ttm) | -3.037 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 355.95M USD |
| Total Cash Per Share (mrq) | 3.65 USD |
| Total Debt (mrq) | 104.09M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.69 |
| Book Value Per Share (mrq) | -0.506 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -239048000 USD |
| Levered Free Cash Flow (ttm) | -103633752 USD |
Profile of FibroGen, Inc.
| Country | United Kingdom |
| State | CA |
| City | San Francisco |
| Address | 409 Illinois Street |
| ZIP | 94158 |
| Phone | 415 978 1200 |
| Website | https://www.fibrogen.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 592 |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Q&A For FibroGen, Inc. Stock
What is a current 0IL8.L stock price?
FibroGen, Inc. 0IL8.L stock price today per share is 1.31 USD.
How to purchase FibroGen, Inc. stock?
You can buy 0IL8.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for FibroGen, Inc.?
The stock symbol or ticker of FibroGen, Inc. is 0IL8.L.
How many shares does FibroGen, Inc. have in circulation?
The max supply of FibroGen, Inc. shares is 706.84K.
What is FibroGen, Inc. Price to Earnings Ratio (PE Ratio)?
FibroGen, Inc. PE Ratio is now.
What was FibroGen, Inc. earnings per share over the trailing 12 months (TTM)?
FibroGen, Inc. EPS is -3.037 USD over the trailing 12 months.